NasdaqCM:TRVN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Trevena's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TRVN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.9%

TRVN

2.0%

US Biotechs

2.3%

US Market


1 Year Return

57.8%

TRVN

27.6%

US Biotechs

6.7%

US Market

Return vs Industry: TRVN exceeded the US Biotechs industry which returned 26.3% over the past year.

Return vs Market: TRVN exceeded the US Market which returned 6% over the past year.


Shareholder returns

TRVNIndustryMarket
7 Day1.9%2.0%2.3%
30 Day22.0%7.4%-0.7%
90 Day215.7%25.3%17.1%
1 Year57.8%57.8%28.8%27.6%9.0%6.7%
3 Year-38.6%-38.6%34.6%30.2%36.7%27.8%
5 Year-75.9%-75.9%-3.3%-8.8%65.2%46.9%

Price Volatility Vs. Market

How volatile is Trevena's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Trevena undervalued compared to its fair value and its price relative to the market?

5.54x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TRVN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TRVN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TRVN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: TRVN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TRVN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TRVN is overvalued based on its PB Ratio (5.5x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Trevena forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

57.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRVN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRVN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRVN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRVN's revenue (57% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: TRVN's revenue (57% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TRVN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Trevena performed over the past 5 years?

15.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TRVN is currently unprofitable.

Growing Profit Margin: TRVN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TRVN is unprofitable, but has reduced losses over the past 5 years at a rate of 15.6% per year.

Accelerating Growth: Unable to compare TRVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: TRVN has a negative Return on Equity (-88.3%), as it is currently unprofitable.


Next Steps

Financial Health

How is Trevena's financial position?


Financial Position Analysis

Short Term Liabilities: TRVN's short term assets ($29.8M) exceed its short term liabilities ($2.6M).

Long Term Liabilities: TRVN's short term assets ($29.8M) exceed its long term liabilities ($7.6M).


Debt to Equity History and Analysis

Debt Level: TRVN is debt free.

Reducing Debt: TRVN has no debt compared to 5 years ago when its debt to equity ratio was 2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRVN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TRVN has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 4.6% each year.


Next Steps

Dividend

What is Trevena current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TRVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TRVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TRVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRVN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRVN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Carrie Bourdow (57yo)

1.75yrs

Tenure

US$1,568,668

Compensation

Ms. Carrie L. Bourdow has been Chief Executive Officer, President and Director at Trevena, Inc., since October 01, 2018. Ms. Bourdow served as an Executive Vice President and Chief Operating Officer of Tre ...


CEO Compensation Analysis

Compensation vs Market: Carrie's total compensation ($USD1.57M) is about average for companies of similar size in the US market ($USD1.34M).

Compensation vs Earnings: Carrie's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Carrie Bourdow
President1.75yrsUS$1.57m0.17% $289.0k
Mark Demitrack
Senior VP & Chief Medical Officer2.17yrsUS$830.85k0.058% $100.6k
Robert Yoder
Senior VP & Chief Business Officer1.58yrsUS$689.16k0.047% $80.5k
Howard Rockman
Scientific Founderno datano datano data
Barry Shin
Senior VP & CFO1.08yrsno data0.42% $717.2k
Scott Applebaum
Chief Legal and Compliance Officer & Senior VP of Regulatory Affairs0.42yrno datano data
Michael Catalano
Vice President of Marketing2.42yrsno datano data

1.7yrs

Average Tenure

54yo

Average Age

Experienced Management: TRVN's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Carrie Bourdow
President1.75yrsUS$1.57m0.17% $289.0k
Howard Rockman
Scientific Founderno datano datano data
Michael Dougherty
Independent Director6.92yrsUS$81.05k0.0065% $11.3k
Leon Moulder
Independent Chairman7.08yrsUS$101.05k0.14% $241.5k
John LaMattina
Member of the Scientific Advisory Board11.5yrsno datano data
Robert Lefkowitz
Member of Scientific Advisory Boardno datano datano data
Robert Ruffolo
Member of the Scientific Advisory Board11.5yrsno datano data
Maxine Gowen
Director12.67yrsUS$66.05k0.44% $756.7k
Julie McHugh
Independent Director6yrsUS$74.05kno data
Barbara Yanni
Independent Director6yrsUS$83.55k0.0012% $2.0k

7.0yrs

Average Tenure

63yo

Average Age

Experienced Board: TRVN's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.1%.


Top Shareholders

Company Information

Trevena, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Trevena, Inc.
  • Ticker: TRVN
  • Exchange: NasdaqCM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$172.561m
  • Shares outstanding: 107.18m
  • Website: https://www.trevena.com

Number of Employees


Location

  • Trevena, Inc.
  • 955 Chesterbrook Boulevard
  • Suite 110
  • Chesterbrook
  • Pennsylvania
  • 19087
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRVNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2014
6T4DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2014

Biography

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/08 23:58
End of Day Share Price2020/07/08 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.